Similarly, a retrospective analysis of 78 metastatic melanoma patients (AM = 42) with c-Kit mutation or amplification treated with imatinib presented median OS and PFS of all patients of 13.1 and 4.2 months, respectively. This evidence concerns the gene KIT and metastatic melanoma.